iVi Biopharma

iVi Biopharma is a preclinical-stage biotechnology company pioneering the development of in vivo CAR-T cell therapies. Headquartered in Houston, Texas, the company utilizes a proprietary non-viral gene delivery platform to reprogram immune cells directly within the patient's body. This innovative approach bypasses the traditional, costly, and time-consuming ex vivo manufacturing process associated with current CAR-T treatments. iVi Biopharma's pipeline is primarily focused on oncology, targeting both hematologic malignancies and challenging solid tumors. By simplifying the delivery and production of engineered T cells, the company aims to make advanced immunotherapy more accessible and affordable for a broader patient population.